Breast cancer treatment typically involves a combination of approaches, not just one. The specific plan depends on the tumor’s size, whether it has spread, and its biological characteristics, particularly whether it responds to hormones or produces excess amounts of a specific protein called HER2. Most people receive some form of surgery, often followed by additional therapies designed to destroy remaining cancer cells and reduce the chance of recurrence.
How Doctors Decide on a Treatment Plan
Before treatment begins, your cancer is staged using a system that evaluates three things: the size of the tumor, whether cancer has reached nearby lymph nodes, and whether it has spread to distant organs like the bones, lungs, liver, or brain. A tumor 20 millimeters or smaller is classified differently than one larger than 50 millimeters, and cancer found in one to three armpit lymph nodes is a different situation than cancer in ten or more.
Beyond staging, a biopsy reveals the tumor’s biology. About 70 to 80 percent of breast cancers are hormone receptor-positive, meaning they grow in response to estrogen or progesterone. Another 15 to 20 percent overproduce a growth-promoting protein called HER2. A smaller subset, called triple-negative breast cancer, tests negative for all three markers and requires a different strategy. These biological details often matter as much as the stage in determining which treatments you’ll receive.
The stakes vary significantly by how early the cancer is caught. When breast cancer is still confined to the breast, the five-year relative survival rate is essentially 100 percent. When it has spread to regional lymph nodes, that drops to about 87 percent. For cancer that has metastasized to distant organs, the five-year survival rate is around 33 percent. Nearly two-thirds of breast cancers are diagnosed at the localized stage.
Surgery: Lumpectomy vs. Mastectomy
Surgery is the cornerstone of treatment for most breast cancers that haven’t spread to distant sites. The two main options are a lumpectomy, which removes only the tumor and a margin of healthy tissue around it, and a mastectomy, which removes the entire breast.
Lumpectomy is the standard choice for early-stage breast cancer, where the tumor is small relative to the breast and confined to one area. The goal is to preserve as much of the breast as possible while ensuring clean margins, meaning no cancer cells are found at the edges of the removed tissue. If the margins aren’t clear, a second surgery may be needed. A mastectomy is typically recommended when a tumor is large, when there are multiple tumors in different areas of the breast, or when a patient prefers it for personal or genetic risk reasons. For early-stage disease, long-term survival rates are comparable between the two approaches when lumpectomy is paired with radiation.
Radiation Therapy After Surgery
Radiation uses high-energy beams to kill cancer cells that may remain in the breast, chest wall, or nearby lymph nodes after surgery. It’s almost always recommended after a lumpectomy and sometimes after a mastectomy if the tumor was large or lymph nodes were involved.
The traditional schedule involves daily treatments five days a week for five to six weeks. This longer course is still common when radiation needs to cover lymph node areas. But shorter schedules have become increasingly standard. Whole-breast radiation can now often be completed in one to four weeks, and partial-breast radiation, which targets only the area where the tumor was, may be finished in five days or less. These shorter courses deliver slightly larger doses per session but produce equivalent outcomes with less disruption to daily life.
Chemotherapy
Chemotherapy uses drugs that travel through the bloodstream to kill fast-dividing cancer cells throughout the body. It’s typically recommended when there’s a higher risk that cancer cells have spread beyond the breast, even if imaging doesn’t show it. This includes larger tumors, cancers that have reached lymph nodes, triple-negative breast cancers, and some HER2-positive cancers.
The two most commonly used drug classes work in different ways. One type damages cancer cell DNA directly, causing the cells to break apart and die. The other interferes with the internal scaffolding cells need to divide, freezing them mid-division and triggering cell death. Treatment is given in cycles, with rest periods between rounds to allow healthy cells to recover. Chemotherapy may be given before surgery (to shrink a tumor) or after surgery (to eliminate any remaining cancer cells).
Side effects are common because chemotherapy affects all rapidly dividing cells, not just cancerous ones. Fatigue, nausea, hair loss, and increased vulnerability to infection are typical during treatment. Nearly all patients experience fatigue at some point, and many deal with sleep problems and a form of mental fogginess sometimes called “chemo brain.” Research consistently shows that exercise and behavioral strategies are more effective at managing these lingering symptoms than medications alone, which tend to provide only temporary relief.
Hormone Therapy for ER/PR-Positive Cancers
If your cancer tests positive for estrogen or progesterone receptors, hormone therapy is a central part of treatment. These drugs work by cutting off the hormonal fuel that drives tumor growth. Unlike chemotherapy, which is given for a defined period, hormone therapy is typically taken daily for five to ten years after surgery.
The approach differs depending on whether you’re pre- or postmenopausal. Premenopausal women are often prescribed tamoxifen, which blocks estrogen from binding to cancer cells. It works in both age groups and is also the standard first-line treatment for men with hormone-positive breast cancer. Postmenopausal women more commonly take aromatase inhibitors, which block the enzyme the body uses to produce estrogen outside the ovaries. For premenopausal women at higher risk, doctors may combine an aromatase inhibitor with a drug that temporarily shuts down ovarian function.
Hormone therapy can also be used before surgery to shrink tumors in postmenopausal women who aren’t candidates for chemotherapy or who can’t have surgery right away. For advanced or metastatic hormone-positive breast cancer, these same drugs remain a primary treatment option, sometimes combined with newer targeted therapies.
Targeted Therapy for HER2-Positive Cancers
About one in five breast cancers overproduce HER2, a protein that promotes aggressive cell growth. Targeted therapies for HER2-positive cancer attach directly to the HER2 protein on the surface of cancer cells, blocking the growth signals and flagging the cells for destruction by the immune system.
Trastuzumab is the foundational drug in this category and has been the standard of care for HER2-positive breast cancer for over two decades. It’s often combined with pertuzumab, which binds to a different part of the HER2 protein, providing a more complete blockade. These drugs are given alongside chemotherapy before or after surgery, and treatment with trastuzumab typically continues for about a year total.
A newer class called antibody-drug conjugates takes this a step further. These are essentially targeted delivery vehicles: they use the same antibody that recognizes HER2 to carry a potent cell-killing drug directly inside the cancer cell. This concentrates the toxic payload where it’s needed and reduces damage to healthy tissue. Two of these conjugates are now widely used, one carrying a drug that disrupts cell division and another carrying a drug that damages DNA. They’ve become particularly important for cancers that don’t fully respond to initial HER2-targeted treatment.
Immunotherapy for Triple-Negative Breast Cancer
Triple-negative breast cancer lacks the receptors that hormone therapy and HER2-targeted drugs act on, which historically left chemotherapy as the only systemic option. Immunotherapy has changed that picture. Pembrolizumab is currently the only immunotherapy drug approved for breast cancer, and it works by releasing a brake on the immune system, allowing immune cells to recognize and attack cancer cells they would otherwise ignore.
For early-stage triple-negative breast cancer, pembrolizumab is given with chemotherapy before surgery to help shrink the tumor. After surgery, it may continue on its own for a period to target any remaining microscopic disease. For triple-negative breast cancer that has metastasized or come back and can’t be surgically removed, pembrolizumab combined with chemotherapy is also an option.
What Treatment Looks Like Day to Day
Most breast cancer treatment unfolds over several months to a year for early-stage disease. A typical sequence might start with chemotherapy for several months before surgery, followed by the surgery itself, then radiation over a few weeks, and finally years of hormone therapy if the cancer is hormone-positive. Not everyone gets every treatment. Someone with a small, hormone-positive, HER2-negative tumor caught early might need only a lumpectomy, a few weeks of radiation, and hormone therapy pills.
Recovery from lumpectomy is usually a matter of days to a couple of weeks. Mastectomy recovery takes longer, especially if reconstruction is done at the same time. Radiation side effects, primarily skin irritation and fatigue, tend to peak toward the end of treatment and resolve within weeks. Chemotherapy side effects come and go with each cycle, with most people feeling worst in the days immediately following an infusion. Hormone therapy side effects are milder but persistent, often including hot flashes, joint stiffness, and mood changes that can last for the duration of treatment.
The combination of fatigue, sleep disruption, and cognitive fog can linger well beyond active treatment. Regular physical activity, even moderate walking, has shown stronger and more sustained benefits for these symptoms than any medication currently available. Many cancer centers now incorporate exercise programs and behavioral support as standard parts of survivorship care.